Company Description
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters.
In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel.
The company was incorporated in 2000 and is headquartered in Mason, Ohio.
| Country | United States |
| Founded | 2000 |
| IPO Date | Aug 5, 2005 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 1,300 |
| CEO | Michael Carrel |
Contact Details
Address: 7555 Innovation Way Mason, Ohio 45040 United States | |
| Phone | 513 755 4100 |
| Website | atricure.com |
Stock Details
| Ticker Symbol | ATRC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001323885 |
| CUSIP Number | 04963C209 |
| ISIN Number | US04963C2098 |
| Employer ID | 34-1940305 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Michael H. Carrel | Chief Executive Officer, President and Director |
| Angela L. Wirick | Chief Financial Officer |
| Douglas J. Seith | Chief Operating Officer |
| Salvatore Privitera J.D. | Chief Technical Officer |
| Karl S. Dahlquist CCEP, J.D. | Chief Legal Officer |
| Dr. Vinayak Doraiswamy Ph.D. | Chief Scientific Officer |
| Valerie Storch-Willhaus | Vice President of Corporate Marketing and Communications |
| Justin J. Noznesky | Chief Marketing and Strategy Officer |
| Deborah Yount | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 7, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 144 | Filing |
| Feb 14, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 14, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |